---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Definition and etiology"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Definition and etiology. Topics: Clinical definition, Sponsor description of the disease, Original descriptions by Rett and by Hagberg, Variant (atypical) Rett syndrome, and 6 further topics. 10 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Clinical definition

> “Rett syndrome (RTT) is a severe, progressive, neurodevelopmental disorder, which affects predominantly females. In most cases, RTT is associated with pathogenic variants in MECP2. MeCP2, the protein product of MECP2, is known to regulate gene expression and is highly expressed in the brain. RTT is characterized by developmental regression of spoken language and hand use that, with hand stereotypies and impaired ambulation, constitute the four core diagnostic features.”

Source: [Gold et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39511247/)

> “Classic Rett syndrome, a progressive neurodevelopmental disorder primarily affecting girls, is characterized by apparently normal psychomotor development during the first six to 18 months of life, followed by a short period of developmental stagnation, then rapid regression in language and motor skills, followed by long-term stability. During the phase of rapid regression, repetitive, stereotypic hand movements replace purposeful hand use.”

Source: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/)

> “The clinical picture associated with typical RTT is defined by a regression of purposeful hand use and spoken language, with the development of gait abnormalities and hand stereotypies. After the period of regression, a stage of stabilization and potentially even improvement ensues, with some individuals partially regaining skills.”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.1-2"></a>

### Sponsor description of the disease

> “Rett syndrome, a rare progressive neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2, or MeCP2, which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy.”
> “Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.2.1.1-3"></a>

### Original descriptions by Rett and by Hagberg

> “Rett Syndrome (RTT, MIM 312750), an X-linked neurodevelopmental condition characterized by loss of spoken language and hand use with the development of distinctive hand stereotypies, was originally described in the 1960’s by Andreas Rett”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

> “Believing the symptoms to be consistent with a metabolic disorder, he called it ‘cerebroatrophic hyperammonaemia’ in a 1966 German publication”

Source: [Kyle et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5830535/)

> “Thirty-five patients, exclusively girls, from three countries had a uniform and striking progressive encephalopathy.”
> “The condition is similar to a virtually overlooked syndrome described by Rett in the German literature.”

Source: [Hagberg et al. (1983)](https://pubmed.ncbi.nlm.nih.gov/6638958/)

<a id="topic-2.2.1.1-4"></a>

### Variant (atypical) Rett syndrome

> “Variant Rett syndrome. Females with variant Rett syndrome exhibit a broader spectrum of clinical features than those observed in classic Rett syndrome. At the more severe end of the spectrum, development is delayed from very early infancy; congenital hypotonia and infantile spasms are also seen. At the milder end of the spectrum, regression is less dramatic and intellectual disability is much less severe; some speech may be preserved.”

Source: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/)

<a id="topic-2.2.1.1-5"></a>

### Genetic cause: MECP2 variants

> “Our study reports the first disease-causing mutations in RTT and points to abnormal epigenetic regulation as the mechanism underlying the pathogenesis of RTT.”

Source: [Amir et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10508514/)

> “Using a battery of modern mutation detection assays, mutations in MECP2 can be found in 95–97% of individuals with typical RTT”
> “Importantly, even using the best methodologies, 3–5% of individuals who strictly meet clinical criteria for RTT do not have an identified mutation in MECP2, indicating that a mutation in this gene is not required to make the diagnosis of typical RTT”
> “The situation is more dramatic in atypical cases, with only 50–70% having identified mutations in MECP2”
> “Because MECP2 mutations are neither necessary nor sufficient to make the diagnosis of RTT, RTT remains a clinical diagnosis.”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.1-6"></a>

### Variants in other genes in atypical presentations

> “Recent work has found mutations in different loci associated with these variant forms, with mutations in CDKL5 found in early seizure variant cases”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.1-7"></a>

### MECP2-related disorders nomenclature

> “We propose that all individuals with clinical disorders and MECP2 mutations be called MECP2-related disorders, which includes RTT and other neurological conditions associated with MECP2 mutations.”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.1-8"></a>

### De novo occurrence and X-linked inheritance

> “MECP2 disorders are inherited in an X-linked manner. More than 99% are simplex cases (i.e., a single occurrence in a family), resulting from a de novo pathogenic variant or possibly from inheritance of the pathogenic variant from a parent who has germline mosaicism. Rarely, a MECP2 variant may be inherited from a heterozygous mother in whom favorable skewing of X-chromosome inactivation results in minimal to no clinical findings. When the mother is a known heterozygote, the risk to her offspring of inheriting the MECP2 variant is 50%.”

Source: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/)

> “Although Rett syndrome is a genetic disorder, less than 1% of recorded cases are passed from one generation to the next. Most cases are spontaneous, which means the mutation occurs randomly.”

Source: [NINDS](https://www.ninds.nih.gov/health-information/disorders/rett-syndrome)

<a id="topic-2.2.1.1-9"></a>

### Paternal origin of de novo variants and female predominance

> “RTT almost exclusively affects female offspring and, in 99.5% of all cases, is sporadic and due to de novo mutations in the MECP2 gene.”
> “We analyzed the parental origin of MECP2 mutations in sporadic cases of RTT, by analysis of linkage between the mutation in the MECP2 gene and intronic polymorphisms in 27 families with 15 different mutations, and we found a high predominance of mutations of paternal origin in 26 of 27 cases (P<.001).”
> “We conclude that de novo mutations in RTT occur almost exclusively on the paternally derived X chromosome and that this is most probably the cause for the high female:male ratio observed in patients with RTT.”

Source: [Trappe et al. (2001)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1226090/)

<a id="topic-2.2.1.1-10"></a>

### Males with MECP2 variants

> “Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities. Death often occurs before age two years.”

Source: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/)

> “To enhance understanding of the phenotypic spectrum present in these individuals, we identified thirty males with MECP2 mutations in the RTT Natural History Study databases. A wide phenotypic spectrum was observed, ranging from severe neonatal encephalopathy to cognitive impairment. Two males with a somatic mutation in MECP2 had classic RTT.”
> “careful review of the clinical history determined that an additional 12/28 subjects met criteria for atypical RTT, but with more severe clinical presentation and course, and less distinctive RTT features, than females with RTT, leading to the designation of a new diagnostic entity, Male RTT Encephalopathy.”

Source: [Neul et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6488031/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
